3 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $25M | -$88M | 0.0% | -380.9% | -$89M | — | $42M |
| 2024 | $52M | -$78M | 0.0% | -170.0% | -$112M | — | $27M |
| 2023 | $45M | -$68M | 0.0% | -175.4% | -$101M | — | $141M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $1M | -$23M | 0.0% | -1970.1% | -$21M | — | $25M |
| Dec '25 | $4M | -$23M | 0.0% | -623.0% | -$24M | — | $42M |
| Sep '25 | $9M | -$20M | 0.0% | -263.8% | -$21M | — | $33M |
| Jun '25 | $9M | -$20M | 0.0% | -246.5% | -$21M | — | $27M |
| Mar '25 | $4M | -$25M | 0.0% | -674.1% | -$23M | — | $29M |
| Dec '24 | $10M | -$23M | 0.0% | -214.5% | -$27M | — | $27M |
| Sep '24 | $12M | -$19M | 0.0% | -194.4% | -$28M | — | $25M |
| Jun '24 | $20M | -$11M | 0.0% | -84.3% | -$27M | — | $61M |
| Mar '24 | $11M | -$25M | 0.0% | -260.2% | -$31M | — | $103M |
| Dec '23 | $12M | -$19M | 0.0% | -162.9% | -$22M | — | $141M |
| Sep '23 | $12M | -$20M | 0.0% | -181.1% | -$26M | — | $102M |
| Jun '23 | $11M | -$13M | 0.0% | -158.4% | -$29M | — | $52M |
| Mar '23 | $9M | -$16M | 0.0% | -207.2% | -$24M | — | $96M |
How the market has priced MGX against its own fundamentals since 2024-02 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 2 years, Metagenomi Therapeutics, Inc.'s revenue has declined 24.9% per year. These are computed facts, not advice.
As of FY2025, Metagenomi Therapeutics, Inc. reported — of total debt against $42M of cash.
In FY2025, gross margin was —, operating margin -380.9%, and net margin -348.5%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.